{"drugs":["Eptotermin Alfa"],"mono":{"0":{"id":"930425-s-0","title":"Generic Names","mono":"Eptotermin Alfa"},"1":{"id":"930425-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930425-s-1-4","title":"Adult Dosing","mono":"<ul><li>eptotermin alfa has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Lumbar spinal fusion, Posterolateral, with autograft failure or contraindication - Spondylolisthesis:<\/b> (Opgenra) 1 unit SURGICALLY IMPLANTED on each side of the spine; MAX, 2 units (European Medicines Agency-approved dosing)<\/li><li><b>Repair of nonunion of tibia, Nonunion of at least 9 months duration, secondary to trauma, with autograft failure or unfeasibility:<\/b> (Osigraft) SURGICALLY IMPLANT amount of reconstituted product from 1 or 2 vials that approximates the size of the bone defect; MAX, 2 vials (European Medicines Agency-approved dosing)<\/li><\/ul>"},"1":{"id":"930425-s-1-5","title":"Pediatric Dosing","mono":"eptotermin alfa is contraindicated in children, adolescents, and the skeletally immature "},"3":{"id":"930425-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Lumbar spinal fusion, Posterolateral, with autograft failure or contraindication - Spondylolisthesis<\/li><li>Repair of nonunion of tibia, Nonunion of at least 9 months duration, secondary to trauma, with autograft failure or unfeasibility<\/li><\/ul>"}}},"3":{"id":"930425-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930425-s-3-9","title":"Contraindications","mono":"<ul><li>arthrodesis treatment resulting from tumor or metabolic bone disease<\/li><li>autoimmune disease, including Crohn disease (Opgenra), rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjogren syndrome, and dermatomyositis\/polymyositis<\/li><li>bone morphogenetic protein product exposure, history of (Opgenra)<\/li><li>concomitant use of chemotherapy, radiation therapy, immunosuppressive therapy (Osigraft)<\/li><li>hypersensitivity to eptotermin alfa, or any component of the product, or to collagen (Osigraft)<\/li><li>infection, active, at site of non-fusion, or active systemic infection (Osigraft), or history of recurring infections (Opgenra)<\/li><li>malignancy, active, or receiving treatment for malignancy (Opgenra)<\/li><li>non-fusion resulting from pathological fractures, metabolic bone disease, or tumors (Osigraft)<\/li><li>pediatric patients less than 18 years old<\/li><li>skeletally immature individuals<\/li><li>skin coverage and vascularity, inadequate, at the non-fusion site<\/li><li>tumor in the area of the non-fusion (Osigraft)<\/li><li>vertebral fractures (Osigraft)<\/li><\/ul>"},{"id":"930425-s-3-10","title":"Precautions","mono":"<ul><li>antibodies, neutralizing, may develop; test for antibodies in serum if immune-mediated undesirable effect, including lack of effectiveness, is suspected<\/li><li>biomechanical strength is not achieved with product for non-fusion of tibia; motion in the non-fusion site may disrupt the fracture healing process; intramedullary nailing was used to stabilize tibial non-fusion site in controlled clinical trials; additional surgery may be required (Osigraft)<\/li><li>cardiovascular disease, known history; exacerbation following surgery may occur; close monitoring postsurgery recommended (Opgenra)<\/li><li>comorbidities, preexisting (eg, cardiovascular, respiratory, genitourinary disorders, neoplasms); exacerbation following surgery has been reported  (Opgenra)<\/li><li>concomitant use with synthetic bone void filler not recommended; product migration, local inflammation, and infection may occur<\/li><li>infection, history of frequent occurrence; exacerbation following surgery may occur; close monitoring postsurgery recommended (Opgenra)<\/li><li>liver impairment (Opgenra)<\/li><li>ossification, ectopic, may occur in surrounding tissue and cause potential complications if material is dislodged from the fusion site; prevent leakage due to irrigation, defective closure of surrounding tissue, and inadequate hemostasis; follow-up with CT or x-ray to evaluate medial bone formation (Opgenra)<\/li><li>pregnancy; use not recommended unless benefit outweighs risk (Opgenra)<\/li><li>readministration not recommended; risk of autoimmunity towards endogenous bone morphogenetic proteins<\/li><li>renal impairment (Opgenra)<\/li><li>use in areas outside lumbar spine not recommended (Opgenra)<\/li><li>women of childbearing potential; use effective contraception up to at least 12 months after treatment (Osigraft), or at least 2 years after treatment (Opgenra)<\/li><\/ul>"},{"id":"930425-s-3-11","title":"Pregnancy Category","mono":"D (AUS)<br\/>"},{"id":"930425-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930425-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Swelling, Localized (lumbar spinal fusion, 0.1% to less than 1%; tibial non-fusion, 1% to less than 10%), Wound dehiscence (lumbar spinal fusion, 1% to less than 10%), Wound discharge (lumbar spinal fusion, 1% to less than 10%), Wound erythema (1% to less than 10%), Wound tenderness (tibial non-fusion, 1% to less than 10%)<\/li><li><b>Immunologic:<\/b>Postoperative infection (lumbar spinal fusion, 1% to less than 10%)<\/li><li><b>Musculoskeletal:<\/b>Heterotopic ossification (1% to less than 10%), Pseudoarthrosis (lumbar spinal fusion, 1% to less than 10%)<\/li><\/ul>"},"6":{"id":"930425-s-6","title":"Drug Name Info","sub":{"2":{"id":"930425-s-6-19","title":"Class","mono":"Bone Morphogenetic Protein<br\/>"},"3":{"id":"930425-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930425-s-9","title":"Administration","mono":"<b>Intraosseous<\/b><br\/><ul><li>(Opgenra) reconstitution of 1 vial containing 1 g powder with 3.3 mg eptotermin alfa and 1 vial containing 230 mg carmellose powder provides 1 unit of eptotermin alfa product<\/li><li>(Opgenra) remove stoppers from eptotermin alfa vial and carmellose powder vial; do not insert a needle through the stoppers; place contents of the 2 vials into a sterile bowl and do not tap the bottom of the vial when transferring contents; slowly add 2.5 mL NS and gently stir with sterile spatula; use immediately after reconstitution<\/li><li>(Opgenra) prior to administration, debride and decorticate bone and provide hemostasis and irrigation as necessary; apply product to each side of spine, bridging the dorsal surfaces of the adjacent transverse processes; suture soft tissues to close wound; do not place drain in the implant or fusion site; use subQ drain if possible<\/li><li>(Osigraft) remove stopper from eptotermin alfa vial; do not insert a needle through the stoppers; transfer contents of eptotermin alfa vial to sterile bowl, reconstitute with 2 to 3 mL of NS, and mix; do not tap bottom of vial; use immediately after reconstitution<\/li><li>(Osigraft) prior to administration, debride fibrous, necrotic, or sclerotic tissue and decorticate bone fragments; provide hemostasis and irrigation as necessary; apply an amount of reconstituted product that approximates the size of the bone defect with sterile spatula or curette; do not use suction or irrigation directly at implant site; suction adjacent to implant site or blot area with sterile sponge; suture soft tissues to close wound; do not place a drain in the implant site; use a subQ drain if required<\/li><\/ul>"}}}